Royalty Report: Drugs, Drug Discovery, Disease – Collection: 243481

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Drug Discovery
  • Disease
  • Therapeutic
  • Assay
  • Diagnostic
  • Proteins
  • Content
  • Test/Monitoring
  • Data Management
  • Biotechnology
  • Medical Info
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 243481

License Grant
The Licensor of the United Kingdom and Licensee wish to collaborate on the discovery and development of Hepatitis C inhibitors which act through the viral replicase enzyme.

The United Kingdom Licensor grants an exclusive license, under the Licensor Patents and under Licensor Know-How, to make, have made, use, import, offer to sell, sell and have sold Products in the Territory. Licensor also grants the right to sublicense.

This agreement also includes a non-exclusive grant back to the Licensor.

License Property
The Licensors library consists of Millions of compounds for potential use in high throughput screening are available for purchase from commercial suppliers.  Licensor has used state-of-the-art molecular design software to analyse these commercial compound libraries both for chemical diversity and drug potential, which are critical parameters in developing novel lead compounds. On the basis of these analyses, Licensor has purchased a unique set of chemically diverse, drug-like molecules. Licensors library has also been selected to avoid poor chemical starting points for drug design. The Licensor Library currently contains approximately 50,000 compounds and all of these will be evaluated in the hepC polymerase primary assay.  Compounds which demonstrate activity in the primary assay, will be defined as selected compounds. All other compounds will remain proprietary to Licensor.

Licensee sourced compounds mean compounds supplied by Licensee to Licensor for the purpose of screening by Licensor pursuant to the Research Program in the HCV Replicase Assay.

Field of Use
The primary assay to be used in the research program will determine the inhibitory effects of compounds from Licensor or Licensee libraries on a truncated form of the Hepatitis C RNA polymerase.

The Parties wish to collaborate on the discovery and development of Hepatitis C inhibitors which act through the viral replicase enzyme.

IPSCIO Record ID: 222558

License Grant
For the Compounds and Products, Licensor grants an exclusive license under the Licensor Technology and Licensors interest in the Collaboration Technology, exclusive even as to Licensor and its Affiliates, to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory. It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.

For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to  Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.

For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each  grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows  the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.

For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.

License Property
Licensor has developed proprietary technologies relating to the design and preparation of encoded compound libraries based upon combinatorial chemistry.  'Licensor Technology' shall mean Existing Licensor Patent Rights, Existing Licensor Know-How, and Licensor Improvements (with some exceptions).

Product means any Agreement Product or Licensees Product.

Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.

Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.

Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.

Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'

Field of Use
This agreement field relates to assays, compound screening methods and biological research tools used to design, prepare and screen compound libraries against Licensees biological targets.

IPSCIO Record ID: 249718

License Grant
Licensor grants an exclusive, worldwide, right and license, within the Territory and within the Field, to use the Licensor Know-How and Patent Rights and undivided interest in any Program Intellectual Property and Program Patent Rights that are jointly owned by Licensor and Licensee, as embodied in or related to Designated Compounds, to identify, research, develop, make, have made and use such Designated Compound to develop Licensed Products and to develop, make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Licensed Products; provided, that the exclusivity of such license shall be subject in the case of Generic Patent Rights to the retained rights.
License Property
The licensed property is
(a) the NeoMorph Screening Library,
(b) the NeoMorph Focused Libraries,
(c) ALIS and QSCD,
(d) the Preliminary Compounds,
(e) the Primary Active Compounds,
(f) the Selected Compounds, together with, where applicable, any analogs, derivatives, fragments, sub-cellular constituents or expression products thereof made by Licensor, and
(g) any other tangible materials provided by Licensor to Licensee for use in the conduct of the Programs.

The NeoMorph Screening Library consists of approximately 10,000,000 diverse small organic compounds.

Field of Use
Field means the diagnosis, prevention and/or treatment of any and all diseases in humans.

Licensor synthesize small molecule compounds as mixtures in a format that enables ALIS to efficiently screen proteins. Our proprietary NeoMorph library, consisting of over 10 million diverse small molecules, is stored as approximately 5,000 mixtures, each containing approximately 2,000 mass-encoded compounds. We use proprietary software to ensure that each small molecule compound within a mixture can be uniquely identified by its mass. This obviates the need for artificial tagging methods, which adds preparation time and cost, and may interfere with the screening process.

Under this drug discovery collaboration, Licensor agreed to screen a number of proteins supplied to us by Licensee. Licensor maintains the option to develop some or all of the small molecule compounds Licensor identify.

IPSCIO Record ID: 249719

License Grant
Licensor grants the Japanese Licensee an exclusive, worldwide, right and license, within the Territory, to use the Licensor Know-How and Patent Rights and Licensors undivided interest in any Program Intellectual Property and Joint Program Patent Rights, as embodied in or related to any Designated Compounds, to research, develop, make, have made and use such Designated Compound to develop Licensed Products and to make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Licensed Products.

This agreement includes non-exclusive terms as well.

License Property
The licensed property includes
(a) the Ne0Morph Screening Library,
(b) the NeoMorph Focused Libraries,
(c) ALIS and QSCD,
(d) the Candidate Compound A,
(e) the Candidate Compound B,
(d) the Candidate Compound C, together with, where applicable, any analogs, derivatives, fragments, sub-cellular constituents or expression products thereof and
(e) any other tangible materials provided by Licensor to Licensee for use in the conduct of the Program, which is Controlled by Licensor, primarily relates to a Designated Compound or Licensed Products, whether or not patentable.

NeoMorph Chemistry means the process, proprietary to Licensor, of forming libraries and sub-libraries of discrete compounds by coupling a broad set of diverse cores with diverse sets of building blocks employing proprietary mass-coding algorithms.

NeoMorph Focused Libraries means those compounds synthesized by Licensor derived from Active Compounds identified by Licensee in bioassays or functional assays NeoMorph Screening Library means the entire collection of libraries consisting of mass-encoded small molecule organic compounds owned by Licensor and developed with NeoMorph Chemistry, comprising at least 10,000,000 different compounds.

Licensee is interested in identifying potential pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets. Licensor has certain technology and know-how, including screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Field of Use
The Licensees intended use is for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

The Field means treatment of any disease in humans.

IPSCIO Record ID: 223145

License Grant
Licensor grants to Licensee such rights that it has to grant a worldwide, exclusive license, with right to sublicense, to develop, make, have made, use, sell, offer for sale, have sold, import and have imported Licensed Products, under any Patent Rights owned by Licensor that would otherwise be infringed by Licensee but for this license, including Research Program Patent Rights, and under the Know-how developed by Licensee relating to the Licensed Products, including the Research Program Know-how.

This DiscoverWorksâ„¢ agreement is a research and development collaboration to identify Initial Hits, Improved Hits, Program Lead Compounds and Pre-Clinical Lead Compounds active against selected targets, and suitable, if required, for medicinal chemistry optimization, that may be developed and commercialized.

License Property
The patents include System and method of automatically generating chemical compounds with desired properties, and, Microplate thermal shift assay apparatus for ligand development and multi-variable protein chemistry optimization.

Licensed Product means any commercial product containing an Active Compound as an active ingredient.

Active Compound means a Program Lead Compound or a Pre-Clinical Lead Compound identified in the course of the Research Program, or compound further optimized from such a Program Lead Compound or a Pre-Clinical Lead Compound.

Chemical Optimization means the design, synthesis and identification of Improved Hits, Program Lead Compounds and Pre-Clinical Lead Compounds using DiscoverWorksâ„¢ Technology and other technologies.

DiscoverWorks™ Technology means DirectedDiversity® Technology and ThermoFluor® Technology.

DirectedDiversity(R) Technology means the descriptions, figures and claims of the Patent Rights and associated proprietary Licensor Know-how used to identify potential therapeutic compounds.

ThermoFluor® Technology means the Patent Rights and associated proprietary Licensor Know-how used to evaluate ligand-binding parameters.

Field of Use
The Field means the research, development and commercialization of chemical compounds for use in therapeutic and diagnostic products, except for use in the treatment or cure of Hepatitis C Virus through March 7, 2003 in humans.

IPSCIO Record ID: 209539

License Grant
Licensor grants exclusive worldwide license,  with the right to sublicense, to use such Licensor Technology as is necessary to make, have made,  use, have used, sell, have sold and import Collaboration Compounds or Products in the Territory.
License Property
Product(s) means any product containing a Development Compound.  Development Compound(s) means a compound (or-compounds) which is a Lead Compound or (ii) is derived from a Lead Compound;  and are determined by Licensee to be appropriate for preclinical studies for the purpose of IND filing  by Licensee.

Licensor has developed and owns certain drug discovery technology and intellectual property rights,  including but not necessarily limited to chemical library design software, multi-parallel synthesis and  purification methods,  chemical libraries suitable for biological screening assays and medicinal chemistry.

Licensee desires to utilize Licensor Technology for its drug discovery activities under Licensee know-how concerning the identification and characterization of novel small molecule inhibitors for development as therapeutics for treatment of human disease in the area of oncology.

Field of Use
The Field means all therapeutic indications of human disease for the Collaboration Target.  Licensee desires to utilize Licensor Technology for its drug discovery activities under Licensee know-how  concerning the identification and characterization of novel small molecule inhibitors for development as therapeutics for treatment of human disease in the area of oncology.

IPSCIO Record ID: 215175

License Grant
The parties wish to collaborate in a chemical lead and drug discovery program.  This agreement has an exclusive period.

Subject to and following the decision of Licensor or its licensee to not develop and commercialize with Due Diligence an Active Compound, a Development Compound or Product, as the case may be, Licensor shall grant to Licensee a license, with the right to sublicense, under those Collaboration Patents and know-how which are resulting from the Research Program and related exclusively to the Returned Compound, to make, have made, use, have used, sell, have sold, import and export such Returned Compound in the Territory.

License Property
The Product means any product containing an Active Compound or Development Compound with such compound as the active ingredient or one of the active ingredients, which is the subject of one or more claims under a Collaboration Patent and which is granted regulatory approval by the governing health regulatory authority of the applicable country for marketing in the Field.
Field of Use
The Field means all therapeutic indications in humans for any Target against which a Collaboration Compound, Active Compound, Development Compound or Products may be directed.

IPSCIO Record ID: 332263

License Grant
Included with this collaboration agreement is a third party license.  The collaboration is to screen the Materials against the Assays.

This third party grants the use of the assay.

License Property
Licensor has certain technology utilized by Licensee in all current Combinatorial Libraries.

Hexapeptide Combinatorial Libraries
Four (4) hexapeptide libraries (L, D, acetylated L'and D) are available'· All libraries have the first ·two positions fixed with the remaining four positions consisting or'equimolar mixtures. Proof of concept has been broadly demonstrated· and· potent lead peptfcies identified. Each library contains 52 million peptides.

Tetrapeptide Combi~atorial Libraries.
Three (3) tetrapeptide l'ibraries are available. Two of the tetrapeptide libraries (one nonacetylated and the other·acetylated) contain combinations of 75 different amino acids (L, D and unnatural). Both libraries have the first position fixed with the remaining three positions consisting of equimolar mixtures. Proof of concept has been demonstrated. Each of these libraries contain approximately 30 million peptides.

Field of Use
Licensee provides combinatorial libraries to the Licensor and the Licensor screens such combinatorial libraries against hybrid yeast cells for the purpose of identifying candidates for drug development.

The Parties commenced a joint discovery effort, with acute inflammation as the initial therapeutic focus for the collaboration.

IPSCIO Record ID: 5611

License Grant
Licensor hereby grants to Dutch Licensee an exclusive, worldwide royalty-bearing license (with the right to grant sublicenses subject to notifying Licensor in advance) (i) to make or have made Royalty-Bearing Products incorporating Licensed Compound Sets for use, distribution and sale, (ii) to distribute for sale and sell Royalty-Bearing Products incorporating Licensed Compound Sets, and (iii) to make Active Compounds within a Licensed Compound Set and sell such Active Compounds to a Sublicensee that incorporates those compounds in a Royalty-Bearing Product.
License Property
Compass Array(TM) Library shall mean a collection of ArQule Compounds that is a diverse representative subset of the Mapping Array Libraries produced in calendar year 2001 and used for initial screening of those Mapping Array Libraries.

1. Compass Array Library.
The Compass Array Library is a diverse subset of approximately 25,000 compounds that have been computationally selected to represent at least 12.5% of the ArQule Compounds in the Mapping Array Libraries that Licensor produces 2001.
Licensor will provide approximately 100 micrograms of each Compass Array Library compound dissolved in 25 microliters of 100% DMSO at a concentration of 10 MM in 96-well plates, with 80 filled wells per plate. Because Licensor performs 25% quality control analysis of each Mapping Array Library corresponding to the Compass Array Library, the purity and confirmation of molecular weight is similar to the Mapping Array Library, as described below.

2. Mapping Array Libraries.
A Mapping Array Library is an Array of ArQule Compounds that Licensor generally makes available to its collaborators for screening on a non-exclusive basis. Each Mapping Array Library is based upon a single Chemical Theme.
Licensor will provide approximately 1mg of each Mapping Array Library compound dissolved in 250 microliters of 100% DMSO at a concentration of 10 MM. The compounds will be provided in 96-well plates with up to 80 filled wells per plate. Licensor performs 25% quality control analysis of each Mapping Array Library by HPLC/UV/ELSD for purity and flow injection mass spectrometry for confirmation of molecular weight. Each Mapping Array Library is on average more than 85% pure as determined by HPLC analysis. A Markush structure file defining each chemical theme is supplied with every shipment.

3. Confirmation Samples and Resynthesized Compounds.
As determined by the Research Committee, Licensor shall resynthesize and deliver to Licensee up to twenty-five (25) mg of any Active Compound. Licensor will provide each resynthesized Compound as a dry, solid power or oil with a purity of 95% based on HPLC/UV, ELSD. Typically, parenthesis compounds consist of preparative HPLC-purified, dry, solid compound supplied with proton NMR and mass spectrometry data.

4. Directed Array Compounds.
Unless otherwise agreed to by the Research Committee, all ArQule Compounds delivered as part of the Directed Array Libraries will be provided as 30 mmol of compound in DMSO in 96-well plates with up to 80 filled wells per plate. Licensor performs 100% quality control analysis of each Directed Array compound tested by HPLC/UV/ELSD. The average purity of each Directed Array Library is 85% as determined by HPLC analysis. An SD file is supplied with every shipment.

Field of Use
Field shall mean applications in the life sciences.

IPSCIO Record ID: 249765

License Grant
For the License to Licensed Products,  Licensor grants an exclusive, even as to Licensor, right and license in the Territory and within the Field under the Licensor Patent Rights and to use the Licensor Know-How to make, have made, use, distribute, promote, market, offer for sale, sell, import and export Licensed Products.

For License to Compounds, Licensor grants an exclusive, even as to Licensor, right and license in the Territory and within the Field under the Licensor Patent Rights and to use the Licensor Know-How to research, develop, make, have made, import, export and use the Selected Compounds, and Active Compounds, Improved Active Compounds and Preliminary Compounds of the same Chemotype as such Selected Compounds, Designated Compounds and Derivative Compounds, for research purposes and to develop Licensed Products.

This agreement also includes non-exclusive grants for research.

License Property
Licensor has certain technology and knowhow, including screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Preliminary Compound means any Compound identified as having binding activity when tested against a Target pursuant to the Screening Program and which has Kd values of 10 micromolar or less (i.e., Kd ~ 1 OµM) or such other binding affinity threshold for a specific Target as shall be agreed upon by the parties in writing.

ALIS means the Automated Ligand Identification System, an automated, ultrahigh throughput ligand selection system proprietary to Licensor that is used to identify multiple classes of chemical ligands against a target protein.

OSCD means Quantisized Surface Complimentary Diversity, a model proprietary to Licensor, in terms of which discrete chemical compliments to the surfaces of a Target are defined.

Licensor Know-How means all proprietary information, data and know-how relating to the NeoMorph Screening Library, NeoMorph Focused Libraries, NeoMorph Chemistry, ALIS, QSCD, the Compounds, Active Compounds, approved Active Compounds, Selected Compounds, Derivative Compounds, Designated Compounds or Licensed Products together with, where applicable, any analogs, derivatives or fragments thereof.

Chemotype means a family or group of Compounds closely structurally related to one or more Active Compounds.

Field of Use
The Field means the treatment or prevention of any disease or condition in humans or animals.

Licensee is interested in identifying potential pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

IPSCIO Record ID: 211827

License Grant
The parties wish to collaborate in a chemical lead and drug discovery program.  This agreement has an exclusive period.  Licensee has a non-exclusive right to use Licensors Technology as necessary to conduct activities under the Research Program.  Additionally, Licensor grants an exclusive, worldwide license, with the right to sublicense to use such Licensor Technology as is necessary to make, have made, use, have used, sell, have sold, import and export Active Compounds, Development Compounds and/or Products in the Territory.
License Property
Licensor has developed, licensed and/or owns certain drug discovery technology and intellectual property rights, including chemical library design software, multi-parallel synthesis and purification methods, chemical libraries suitable for high throughput biological screening assays and medicinal chemistry (collectively, 'CombiChem Technology').

Licensee desires to utilize CombiChem Technology for its drug discovery activities under Licensee know-how concerning the identification and characterization of novel small molecule inhibitors for development as therapeutics for treatment of diseases in humans.

Licensee and its Affiliates have developed and own certain drug discovery and intellectual property rights, including certain assays, methods and know how regarding the Initial Target, among other things (collectively 'ICOS Technology').

The Product means any product containing an Active Compound or Development Compound with such compound as the active ingredient or one of the active ingredients, which is the subject of one or more claims under a Collaboration Patent and which is granted regulatory approval by the governing health regulatory authority of the applicable country for marketing in the Field.

The Product means any product containing an Active Compound or Development Compound with such compound as the active ingredient or one of the active ingredients, which is the subject of one or more claims under a Collaboration Patent and which is granted regulatory approval by the governing health regulatory authority of the applicable country for marketing in the Field.

Field of Use
The Field means all therapeutic indications in humans for any Target against which a Collaboration Compound, Active Compound, Development Compound or Products may be directed.

IPSCIO Record ID: 203459

License Grant
Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under Licensors interest in Collaboration Patents, and Collaboration Know-How, in each case solely to develop, make, have made, use, sell, have sold, offer for sale and import Products in the Field in the Territory; provided, however, that Licensor retains such rights under Collaboration Technology as are necessary to perform its obligations under the Research Program.

This agreement also includes Non-Exclusive Cross-Licenses where each Party hereby grants to the other Party a non-exclusive, royalty-free license, without the right to sub-license
(i) under such Partys interest in Collaboration Know-How for the manufacture or formulation of products other than Products, including 'cocktail' and other Combination Products; and
(ii) under such Partys interest in Collaboration Know-How, solely to conduct research in the HCV Field in the Territory.

License Property
Licensor has a research program for the discovery and optimization of nucleoside inhibitors of the NS5b polymerase in hepatitis C virus.

The Collaboration Compound shall mean a Nucleoside that satisfies the chemical and technical requirements set forth, and its Related Compounds and which
(a) is or was synthesized by or for Licensor on or before the Effective Date or during the Research Program Term; or
(b) is a Related Compound to a Collaboration Compound disclosed by Licensor to Licensee pursuant to Identification and Contribution of Collaboration Compounds and which is synthesized by or for Licensee after the Effective Date.

The Collaboration Compound Products shall mean any preparations in final form, bulk form or other form containing as an active pharmaceutical ingredient one or more Selected Compounds.

Field of Use
The Field shall mean all human and animal therapeutic, diagnostic, and prophylactic uses, including, without limitation, the treatment, prevention and prophylaxis of hepatitis C viral infections.

The HCV Field shall mean the treatment of chronic hepatitis C viral infections in humans.

The Collaboration Compound Products are for sale by prescription, over-the-counter or any other method, including without limitation any Combination Product.

IPSCIO Record ID: 249721

License Grant
Licensor grants to the English Licensee
– an exclusive, worldwide, right and license, within the Territory to Licensor Technology and interest in any Program Technology, as embodied in or related to any Preliminary Compound(s), Primary Active Compound(s), QSCD Preliminary Compound(s), QSCD Primary Active Compound(s) and Designated Compounds solely for the purpose of conducting Licensees activities under the Research Collaboration, to research, develop, make, have made, use and import Preliminary Compound(s), Primary Active Compound(s), QSCD Preliminary Compound(s), QSCD Primary Active Compound(s) and Designated Compounds to develop Licensed Product(s); and

– an exclusive, worldwide, right and license, within the Territory, to the Licensors Technology and interest in any Program Technology, as embodied in or related to any Designated Compounds, necessary to make, have made, develop, have developed, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Licensed Product(s).

Licensee may grant sub-licenses.

License Property
Licensed Products shall mean any product whose pharmaceutical composition contains any formulation or dosage of a Designated Compound or any Licensee Derivatives or improvements thereof as a pharmaceutically active ingredient and the development, manufacture, use, or sale of which, absent the rights assigned and licenses granted to Licensee under this Agreement, would infringe the Licensor Technology or which makes use of any Patents comprised in Program Technology with respect to which Licensor is an inventor.

NeoMorph Chemistry shall mean the process, proprietary to Licensor, of forming libraries and sub-libraries of discrete compounds by coupling a broad set of diverse cores with diverse sets of building blocks employing proprietary mass-coding algorithms.

NeoMorph Focuses Libraries shall mean those compounds synthesized by Licensor during the optimization of either the Preliminary Compounds identified from the NeoMorph Screening Library or further optimization of compounds identified in any rounds of optimization.

NeoMorph Screening Library shall mean the constantly expanding collection of libraries consisting of mass-encoded small molecule organic compounds owned by Licensor and developed with NeoMorph Chemistry, currently comprising about 10,000,000 unique compounds.

Preliminary Compound shall mean any Licensor compound identified from the NeoMorph Screening Library which binds an Approved Target with a minimum affinity set by the Steering Committee on an Approved Target by Approved Target basis.

QSCD shall mean Quantisized Surface Complementary Diversity, a technology proprietary to Licensor, in terms of which discrete chemical complements to the surfaces of Approved Targets may be defined.

Field of Use
Licensee is a biopharmaceutical company with an ongoing interest in research, development and commercialization of pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high affinity and functional activity to protein targets for the development, manufacture and commercialization of pharmaceutical products.

IPSCIO Record ID: 299264

License Grant
By this agreement, Licensor shall provide the resources to Licensee and conduct activities under the Research Program. Licensor shall review data and information regarding the Collaboration Target provided by Licensee and derived from the UIL by Licensor, based on such data and information and using the Licensor Technology, design Daughter Libraries; and supply all lead chemistries and synthesize compounds.

Licensee will utilize Licensor Technology for its drug discovery activities under Licensee know-how concerning the identification and characterization of novel small molecule inhibitors.

In addition to Licensees non-exclusive right to use Licensor Technology as necessary to conduct activities under the Research Program, Licensor grants an exclusive, worldwide license, with the right to sublicense to use such Licensor Technology as is necessary to make, have made, use, have used, sell, have sold, import and export Active Compounds, Development Compounds and/or Products in the Territory.

License Property
Licensor has developed, licensed and/or owns certain drug discovery technology and intellectual property rights, including chemical library design software, multi-parallel synthesis and purification methods, chemical libraries suitable for high throughput biological screening assays and medicinal chemistry.

Initial target is Type 3 Phosphodiesterases.

Alternative targets are DNA Polynucleotide kinase (DNA-PK), Poly (ADP-ribase) polymerase (PARP), and, Modulators of the interaction between the G-beta subunit of the G-protein and beta-adrenergic receptor kinase (gB-BARK)

Field of Use
The research focus is for development as therapeutics for treatment of obesity and other diseases in humans.

IPSCIO Record ID: 223156

License Grant
For the Research License for DirectedDiversity Technology, Licensor grants a world-wide, nonexclusive, non- cancelable license under the Licensor DirectedDiversity Technology and Licensor Patents to evaluate the Custom Accessible Libraries, DuPont Custom Accessible Libraries and Licensor Accessible Libraries to identify Target Leads pursuant to the Research Program.

For the Background License in the Field for Active Compounds,  Licensor grants a world-wide, nonexclusive license, with the right to sublicense, under any Custom Accessible Library, Licensor Accessible Library, Licensor Patents or Research Program Patents to the extent that such rights are reasonably necessary for the synthesis or commercialization of Active Compounds in the Field.

Licensor grants rights to screen such compounds against Targets outside of the Field.

License Property
The Licensor DirectedDiversity Technology means 3DP Patents and know-how that relate to generating and utilizing a DirectedDiversity Chemical Library, including but not limited to patents for the System, method, and computer program for at least partially automatically generating chemical compounds having desired properties. This term also includes any discoveries, improvements, inventions and modifications made in the Research Program to the extent that they relate to Licensor DirectedDiversity Technology.

Active Compound means any composition of matter that has been shown to have Protease Inhibition and In Vivo Inhibition activity in the course of the Research Program.

The Custom Accessible Libraries means any DirectedDiversity Chemical Library derived from using Licensor DirectedDiversity Technology and structure activity data provided by Licensee, and includes synthetically accessible compounds generated by Licensor and Licensee in the course of the Research Program derived from any source other than Licensee Compounds or a Licensee Compound Library or the Available Chemicals Directory.

The DirectedDiversity Chemical Library means a computer-generated library of compounds containing integrated structure-activity and synthesis data.

Target means the Photosystem II D1 protease.

Licensor Accessible Libraries means any DirectedDiversity Chemical Library that is generated by Licensor outside of the Research Program.

Licensor Compounds means any compounds that are developed by Licensor outside of the Research Program, including but not limited to compounds that are actually synthesized by Licensor or contained in a Licensor Accessible Library.

Field of Use
The Field means the agricultural use of Active Compounds to inhibit the Target and is for the control of pests and disease.

IPSCIO Record ID: 223154

License Grant
For Ownership of Licensor Accessible Libraries and Licensor Patents, Licensor grants a worldwide, exclusive license, including the right to sublicense, in the Field under such patent to make, have made, use, sell, have sold, import and have imported Licensed Products, provided that Licensor is not contractually prohibited from granting such an exclusive license.  

For the License Under All Licensor Research Program Patents, Licensor grants a non-exclusive license in the Field under all Research Program Patents owned by Licensor to the extent such patents cover making, using, selling, offering for sale or importing a Qualified Lead Compound, an Active Compound or a Licensed Product.

License Property
Licensor DirectedDiversity(R) Technology means Licensor Patents and know-how in effect at the time of the Effective Date of this Agreement that relate to generating and utilizing a DirectedDiversity(R) Chemical Library,  including patents for System, method, and computer program product for at least partially automatically generating chemical compounds with desired properties from a list of potential chemical compounds to synthesize. This term also includes any discoveries, improvements, inventions and modifications made during the Research Program to the extent that they relate to Licensor DirectedDiversity(R) Technology.

DirectedDiversity® Chemical Library means a computer-generated library of compounds containing integrated structure•activity and synthesis data.

Active Compound means a Qualified Lead Compound or a compound derived from a Qualified Lead Compound that has been formally selected by Licensee after recommendation by the Research Steering Committee for preclinical development as evidenced by initiation of a Licensee supported range finding toxicology study to be performed by the Licensee Toxicology Department or its designate.

The Licensed Product means any commercial product containing an Active Compound.  

Licensor Accessible Libraries means anyDirectedDiversity® Chemical Library that is generated by Licensor outside of the Research Program.

Field of Use
The Field is human therapeutic and diagnostic uses of Qualified Lead Compounds or Active Compounds against Targets.

IPSCIO Record ID: 336363

License Grant
For the License Grants for Collaborative Research, Licensor grants an exclusive, worldwide, non-transferable, except as to Japan, license, with the right to sublicense only as it relates to Japan, under the Licensor Technology and Licensors interest in the Collaboration Technology to use such technology solely to the extent necessary or appropriate to carry out Allergans research responsibilities under the Collaboration in the Field.

For the License Grant for Development and Commercial Purposes, Licensor grants the following rights and licenses
–  an exclusive, license under the Licensor Technology and Licensor’s interest in the Collaboration Technology to make, have made, and use Collaboration Lead Compounds in order to conduct necessary preclinical, clinical and other development activities on such Collaboration Lead Compounds to obtain Regulatory Approval for use in the Field as Licensee Products;
–  an exclusive license under the Licensor Technology and Licensor’s interest in the Collaboration Technology to make, have made, use and sell Licensees Products in the Field in the Territory.

License Property
Licensor has discovered compounds that are potent agonists selective for the m1 muscarinic receptor which agonists may be useful in the treatment of ocular disease such as glaucoma.

The patent is titled Compounds with Activity on Muscarinic Receptors.

Licensor Designated Compound shall mean any one of up to ten Active Compounds and their respective enantiomers and isomers, to the extent such isomers are included in the mixture tested and salts thereof,

Licensor Know-How shall mean all tangible or intangible know-how, trade secrets, inventions, whether or not patentable, data, preclinical results, physical, chemical or biological material, and other information and data on or relating to all M1 Muscarinic.

Active Compounds shall mean any M1 Muscarinic that demonstrates the requisite activity levels in the Assays pursuant to the Research Plan

M1 Muscarinics shall mean all m1 muscarinic receptor ligands in Licensor’s possession as of the Effective Date, synthesized during the Research Term pursuant to the Research Plan or in any other Licensor program which selectively targets activation of the m1 muscarinic receptor, or acquired from Third Parties during the Research Term pursuant to the Research Plan or in conjunction with any other Licensor program which selectively targets activation of the m1 muscarinic receptor.

Assays shall mean R-SATâ„¢ assays used to measure activity at all muscarinic receptors and other in vitro molecular assays as determined by the RMC.

Field of Use
The Field shall mean the prevention or treatment of ocular disease.

IPSCIO Record ID: 249720

License Grant
Licensor grants to Swiss Licensee, an exclusive right and license in the Territory and within the Field under the Licensor Patent Rights and to use the Licensor Know-How to make, have made, use, distribute, promote, market, offer for sale, sell, import and export Licensed Products.

This agreement includes non-exclusive terms also.

License Property
Active Compound means any Compound identified as having binding activity when tested against a Target pursuant to the Screening Program and which has Kd values of 10 micromolar or less (i.e., Kd s 10µM) and has demonstrated bioactivity in functional assays against the applicable Target as determined by the Steering Committee.

Compound shall mean all proprietary compounds contained in the NeoMorph Screening Library or any NeoMorph Focused Libraries which are screened by Licensor against one or more Targets in performance of the Screening Program.

Field of Use
Field means the treatment or prevention of any disease or condition in humans or animals.

Licensee is interested in identifying potential pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

Licensor will employ its Automated Ligand Identification System (ALIS) and its neoMorph compound library to help Licensee discover a range of antiviral candidates.

IPSCIO Record ID: 289241

License Grant
Licensor grants the German Licensee an exclusive, worldwide, sublicensable license under the Licensor Technology to research, develop, make, have made, use, sell and import for sale Licensed Compounds and Licensed Products in the Field.

Licensor also grants a nonexclusive, worldwide, sublicensable license under Non-uPA Inhibitor Patents to carry out research and development in respect of uPA Inhibitor Compounds during the Research Program and to use any results of such research and development for the development, manufacture or commercialization of Licensed Compounds and Licensed Products.

Licensor also grants a nonexclusive, worldwide, sublicensable license under Improvements that are Controlled by Licensor during the term of this Agreement to research, develop, make, have made, use, sell and import for sale Licensed Products in the Field.

License Property
Licensor has identified a class of non-peptidic, potent urokinase plasminogen activator (uPA) inhibitors with potential application in various therapeutic fields.

Urokinase Plasminogen Activator (uPA) Inhibitor means a compound that has uPA Ki as determinated by Licensor using a standardized assay reasonably acceptable to the Joint Research Committee less than 1.0 micromolar, and selectivity with respect to the Ki for the compound for uPA of at least 2X with respect to the Ki, as determined by Licensor using a standardized assay reasonably acceptable to the Joint Research Committee, for complement proteases; and selectivity with respect to the Ki for the compound for uPA of at least 10X with respect to the Ki, as determined by Licensor using a standardized assay reasonable acceptable to the Joint Research Committee, for Thrombin, Factor VIIa and Xa.

Licensor Technology means Licensor Know-How and Licensor Patents.

Licensed Compound means a Base Compound or a New Compound.

Licensed Product means a product in finished dosage form containing a Licensed Compound as active ingredient for use in the Field.

Base Compound' means a uPA Inhibitor existing at the Effective Date which falls within the claims of the Patents referenced or falls within the same Chemical Class as such compounds; or falls within Licensors orally available uPA Inhibitor lead series, exemplified by 5-bromo-4 (phenylamino) thiophene-2-carboxamidine hydrochloride and derivatives thereof, as described in the Outline Research Plan.

New Compound means any uPA Inhibitor and members of the same Chemical Class which is identified, discovered, created or synthesized by Licensor in the course of the Research Program; any chemical entity, and any member of the same Chemical Class as such chemical entity, that is identified, discovered, created or synthesized by Licensor and is  discovered during the Research Term, but outside of the Research Program, to be a uPA Inhibitor, to the extent that such chemical entity is Controlled by Licensor; and any chemical entity, and any member of the same Chemical Class as such chemical entity that is identified, discovered, created or synthesized by Licensor and is discovered to be a uPA Inhibitor after the end of the Research Term but within 6 months thereafter, to the extent that such chemical entity is Controlled by Licensor.

Licensor Non-uPA Inhibitor Compounds mean compounds and data relating to such compounds discovered during the Research Program by Licensor which do not constitute uPA Inhibitors but which the Joint Research Committee considers have some biological activity of interest to the Research Program or are of potential commercial interest to Licensee.

Licensor Non-uPA Inhibitor Patents means Patents Controlled by Licensor which claim Non-uPA Inhibitor Compounds.

Licensor Patents means Heteroaryl Amidines, Methyl Amidines and Guanidines…; Patents to be filed by Licensor that claim Licensors orally available uPA Inhibitor lead series, and derivatives thereof, as described in the Outline Research Plan; and Patents that claim New Compounds.

Field of Use
The Field means all uses of Licensed Products for the prevention, treatment, cure or mitigation of all disease states, conditions, disorders and indications in humans.  Among the therapeutic indications under consideratlon are Solid Tumor Growth ( Chemotherapy) e.g. breast. lung, prostate;  Aortic Aneurysm (prevention); Post-PTCA Restenosis (t stent); Rheumatoid Arthtitis, Inflammation; Macular Degeneration; and, Wound Fibrosis (keloid formation, scarring).

IPSCIO Record ID: 283198

License Grant
The Licensee and Swiss Licensor are establishing a research program to identify and validate a limited number of antibacterial targets and to develop a select number of validated assays for high-throughput screening to identify new lead compounds active against such validated targets for the development of drugs.

For Discontinued Licensor Compounds
—  Globally Discontinued Licensor Compounds, in the event that the Swiss Licensor determines, or is forced, to discontinue the development or the global commercialization of a Licensor Product based on a Licensor Compound or an Active Licensee Compound Derivative, such Licensor Compound or Active Licensee Compound Derivative being referred to herein as a Globally Discontinued Novartis Compound, and if Licensor, at its sole discretion, decides to license to a Third Party such Globally Discontinued Licensor Compound, then Licensor shall notify Licensee in writing of the occurrence of the above. Licensee shall then have the right of first refusal.

—  Locally Discontinued Licensor Compounds, in the event that in any country, following the First Commercial Sale of a Licensor Product based on a Licensor Compound or an Active Licensee Compound Derivative, there is a continuous one (1) year period in which no such Licensor Product is sold in such country, and if Licensor, at its sole discretion, decides to license to a Third Party such Locally Discontinued Licensor Compound, Licensor shall notify Licensee in writing of the occurrence of the above. Licensee then
shall have the right of first refusal.

This agreement also includes exclusive, non-exclusive and co-exclusive grants from Licensee to Licensor.

License Property
The know-how, expertise and intellectual property rights pertain to anti-infective drug discovery and to a proprietary drug discovery technology known as VITA TM which couples the validation of the inhibition of a target in an animal model during an established infection with assay development and screening for the discovery of novel drug leads.

VITA TM or Validation In Vivo of Targets for Anti-infectives shall mean Licensors proprietary technology for the validation of anti-infective targets during an established infection in a mouse model system and the development of assays.

The technology couples the validation of target proteins in a pathogen during an established infection in an animal with assay development. The assay is used in high throughput screening to discover novel drug leads that act on therapeutically relevant targets. It is broadly applicable to a number of different targets, including proteins encoded by open reading frames (ORFs), which have previously been intractable to traditional screening paradigms.

Field of Use
Licensee possesses know-how, expertise and intellectual property rights pertaining to antiinfective drug discovery and to a proprietary drug discovery technology known as VITA(TM) which couples the validation of the inhibition of a target in an animal model during an established infection with assay development and screening for the discovery of novel drug leads.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.